Published in Expert Rev Vaccines on October 01, 2006
A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine (2009) 0.92
A super TLR agonist to improve efficacy of dendritic cell vaccine in induction of anti-HCV immunity. PLoS One (2012) 0.80
Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther (2009) 0.80
Targeting lentiviral vectors for cancer immunotherapy. Curr Cancer Ther Rev (2011) 0.80
A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32. J Immunol (2008) 0.79
Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J (2013) 0.78
mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity. Mol Ther (2015) 0.76
Adenovirus co-expressing CD40 ligand and interleukin (IL)-2 contributes to maturation of dendritic cells and production of IL-12. Biomed Rep (2016) 0.75
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res (2009) 2.79
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med (2011) 2.04
Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther (2007) 1.91
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res (2006) 1.39
Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A (2004) 1.25
Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci U S A (2006) 1.23
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther (2008) 1.06
Isolation of cell surface proteins for mass spectrometry-based proteomics. Expert Rev Proteomics (2010) 1.05
Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ leukemia model. PLoS One (2011) 1.02
Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy (2011) 1.01
Lack of susceptibility of cells from patients with Fabry disease to productive infection with R5 human immunodeficiency virus. AIDS (2005) 1.00
A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. J Nucl Med (2010) 1.00
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res (2012) 0.97
Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation (2009) 0.97
In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res (2010) 0.97
H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer (2006) 0.96
On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging. Anal Chem (2014) 0.94
Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J (2006) 0.94
Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med (2013) 0.94
Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica (2012) 0.92
IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med (2009) 0.91
Spontaneous fibroblast-derived pericyte recruitment in a human tissue-engineered angiogenesis model in vitro. J Cell Physiol (2012) 0.89
Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Hum Gene Ther (2011) 0.88
Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. J Cardiol (2010) 0.87
Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther (2008) 0.86
A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol Blood Marrow Transplant (2007) 0.85
Identification of novel mutations in the α-galactosidase A gene in patients with Fabry disease: pitfalls of mutation analyses in patients with low α-galactosidase A activity. J Cardiol (2011) 0.85
Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther (2012) 0.83
In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab (2008) 0.83
A novel tissue-engineered approach to problems of the postpneumonectomy space. Ann Thorac Surg (2011) 0.83
Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. Brain Behav Immun (2013) 0.83
The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J (2003) 0.82
Lentiviral vectors for gene therapy of heart disease. J Cardiol (2007) 0.82
Relaxin-3 and receptors in the human and rhesus brain and reproductive tissues. Regul Pept (2010) 0.82
Harnessing autophagy for cell fate control gene therapy. Autophagy (2013) 0.81
Localized interleukin-12 delivery for immunotherapy of solid tumours. J Cell Mol Med (2013) 0.81
Local long-term expression of lentivirally delivered IL-10 in the lung attenuates obliteration of intrapulmonary allograft airways. Hum Gene Ther (2011) 0.81
Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. Cancer Res (2010) 0.81
Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci (2008) 0.81
Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther (2012) 0.80
Lentiviral vectors in cancer immunotherapy. Immunotherapy (2015) 0.80
Direct injection of kit ligand-2 lentivirus improves cardiac repair and rescues mice post-myocardial infarction. Mol Ther (2008) 0.80
Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther (2009) 0.80
Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells. Mol Ther (2007) 0.79
Neonatal transfer of membrane-bound stem cell factor improves survival and heart function in aged mice after myocardial ischemia. Hum Gene Ther (2012) 0.79
Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity. Mol Ther (2007) 0.79
Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates anti-apoptotic and proliferative mechanisms. FASEB J (2005) 0.79
Vascular endothelial growth factor broadens lentivector distribution in the heart after neonatal injection. J Cardiol (2009) 0.79
Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J (2013) 0.78
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. Mol Cancer Ther (2008) 0.78
Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice. Mol Med (2010) 0.78
Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns. J Immunother (2016) 0.77
Induction of human blood group a antigen expression on mouse cells, using lentiviral gene transduction. Hum Gene Ther (2010) 0.77
The engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer. PLoS One (2013) 0.77
Functional expression of mouse relaxin and mouse relaxin-3 in the lung from an Ebola virus glycoprotein-pseudotyped lentivirus via tracheal delivery. Endocrinology (2006) 0.76
Lentivirally transduced recipient-derived dendritic cells serve to ex vivo expand functional FcRgamma-sufficient double-negative regulatory T cells. Mol Ther (2007) 0.76
IL-10 secretion increases signal persistence of HEMA-MMA-microencapsulated luciferase-modified CHO fibroblasts in mice. Tissue Eng Part A (2009) 0.76
Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease. Mol Biol Rep (2010) 0.75
Cloning, sequencing and characterization of lentiviral-mediated expression of rhesus macaque (Macaca mulatta) interleukin-2 receptor alpha cDNA. Dev Comp Immunol (2005) 0.75
Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients. NDT Plus (2008) 0.75
Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production. Cancer Immunol Immunother (2010) 0.75
Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis. Methods Mol Biol (2015) 0.75
Enhanced filter paper enzyme assay for high-throughput population screening for Fabry disease. Anal Biochem (2005) 0.75
Enhanced effect of vascular endothelial growth factor, thrombopoietin peptide agonist, SCF, and Flt3-L on LTC-IC and reporter gene transduction from umbilical cord blood CD34+ cells. Transfusion (2004) 0.75